Every material Form 8-K Korro Bio, Inc. has filed with the SEC since October 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 3, 2026, Novo Nordisk gave Korro Bio notice that it will terminate their research collaboration and license agreement without cause, effective February 1, 2027. Novo Nordisk did not nominate a second target, and no milestone payments were earned under the agreement. Korro's third-quarter 2026 results showed no collaboration revenue, compared with $1.1 million a year earlier, while the net loss narrowed to $17.5 million from $18.1 million.
Novo Nordisk gave 90 days' notice on November 3, 2026; the termination takes effect February 1, 2027.
Korro's $10.0 million upfront payment and other amounts received are non-refundable, and Korro will not incur early termination penalties.
Collaboration revenue was zero for the quarter ended September 30, 2026, versus $1.1 million a year earlier.
Cash, cash equivalents and marketable securities were $124.8 million at September 30, 2026, with a runway into the second half of 2028.
Korro Bio announced preclinical results for KRRO-111, its development candidate for alpha-1 antitrypsin deficiency (AATD), in an October 22, 2026 press release filed as Exhibit 99.1. The company says the studies, which were conducted in mice and human liver cells, show RNA editing and reduced toxic Z-AAT protein, and it expects a regulatory submission in the first half of 2027. The filing reports no financial results, and the data are preclinical, so they do not show how the drug will perform in people.
In repeat-dose mouse studies, SERPINA1 mRNA editing reached 96% and total AAT concentrations were about 6-fold versus vehicle at Day 57.
Whole liver Z-AAT levels fell 95% relative to vehicle control in immunocompetent C57BL/6-PiZ mice at Day 57.
Korro expects to submit a regulatory filing for KRRO-111 in the first half of 2027.
Korro Bio said it has dosed the first cohort of participants in the ANCHOR Phase 1/2 clinical trial of KRRO-121, a treatment in development for hyperammonemia in urea cycle disorders and hepatic encephalopathy. The filing describes a clinical milestone in an early-stage program and contains no financial results, guidance, or changes to the company's financing or management.
First cohort of healthy volunteers dosed with a single 2mg/kg dose in Australia
Dosing of urea cycle disorder patients expected to start in the first half of 2027
Interim readout expected in the second half of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Korro Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →